Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Tesla acquires AI hardware company for up to $2 billion in stock
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
September 22, 2025 10:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Neutral rating and $27.00 price target on Pfizer (NYSE: PFE).
The analyst comments "This morning PFE announced plans to acquire Metsera (MTSR), a development stage obesity-focused biotech company with a portfolio of candidates (injectable and oral... More
Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
September 22, 2025 9:45 AM EDTWolfe Research analyst Alexandria Hammond reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).
The analyst comments "The path forward for Pfizer and Metsera. Topline data from VESPER-1 and interim data from VESPER-3 for MET-097i remain expected by the end of the month. It is our understanding,... More
